Approximately Six Million Patients in Europe Estimated to Have Atrial Fibrillation —————————————————————————————————– Geographic Expansion of Trial Intended to Support European Regulatory Submissions, European Partnering Discussions and Enrollment Westminster, CO, October 6, 2016 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to the development of...[+more]

  Westminster, CO, October 4, 2016 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it will present a corporate overview at the Dawson James Securities Second Annual Growth Stock Conference.   Date:    ...[+more]

ARCA Biopharma announces 100th patient randomized into the GENETIC-AF Phase 2B/3 clinical trial   GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted  Treatment for Atrial Fibrillation   Outcome of Interim Efficacy Analysis Anticipated in the Second Quarter of 2017 Westminster, CO, August 18, 2016 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company...[+more]

Outcome of GENETIC-AF Clinical Trial Interim Efficacy Analysis Anticipated in the Second Quarter of 2017   GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation   Westminster, CO, August 9, 2016 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported...[+more]

Westminster, CO, May 11, 2016 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended March 31, 2016, and provided a business update. “We are grateful for the continuing support of the physicians, clinical investigators and patients...[+more]

ARCA BIOPHARMA ANNOUNCES 75TH PATIENT ENROLLED IN GENETIC-AF PHASE 2B/3 CLINICAL TRIAL GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation Outcome of Interim Efficacy Analysis of Data from Approximately 150 Patients Anticipated in the Second Quarter of 2017 Westminster, CO, April 18, 2016 – ARCA biopharma, Inc. (Nasdaq:...[+more]

ARCA BIOPHARMA ANNOUNCES FISCAL YEAR 2015 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE  GENETIC-AF Trial Evaluating Gencaro as a Potential Treatment for Atrial Fibrillation Outcome of Interim Analysis of Phase 2B Efficacy Data Anticipated in the First Half of 2017 Westminster, CO, March 17, 2016 – ARCA biopharma, Inc. (Nasdaq: ABIO), a...[+more]

Enrollment for Phase 2B Interim Analysis of Efficacy Data Expected by Year-End 2016 Westminster, CO, January 12, 2016 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today provided an update on GENETIC-AF, the Company’s Phase 2B/3 clinical trial evaluating GencaroTM (bucindolol hydrochloride) as a potential...[+more]

Westminster, CO, November 5, 2015 – ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases, today announced that its President and CEO, Michael R. Bristow, M.D., Ph.D., will give two invited presentations at the American Heart Association Scientific Sessions 2015 (http://my.americanheart.org/professional/Sessions/ScientificSessions/Scientific-Sessions_UCM_316900_SubHomePage.jsp)being held November 7-11, 2015 in...[+more]